PMID- 34215308
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 1750-1326 (Electronic)
IS  - 1750-1326 (Linking)
VI  - 16
IP  - 1
DP  - 2021 Jul 2
TI  - Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.
PG  - 44
LID - 10.1186/s13024-021-00428-5 [doi]
LID - 44
AB  - Novel targets to arrest neurodegeneration in several dementing conditions 
      involving misfolded protein accumulations may be found in the diverse signaling 
      pathways of the Mammalian/mechanistic target of rapamycin (mTOR). As a nutrient 
      sensor, mTOR has important homeostatic functions to regulate energy metabolism 
      and support neuronal growth and plasticity. However, in Alzheimer's disease (AD), 
      mTOR alternately plays important pathogenic roles by inhibiting both insulin 
      signaling and autophagic removal of beta-amyloid (Abeta) and phospho-tau (ptau) 
      aggregates. It also plays a role in the cerebrovascular dysfunction of AD. mTOR 
      is a serine/threonine kinase residing at the core in either of two multiprotein 
      complexes termed mTORC1 and mTORC2. Recent data suggest that their balanced 
      actions also have implications for Parkinson's disease (PD) and Huntington's 
      disease (HD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis 
      (ALS). Beyond rapamycin; an mTOR inhibitor, there are rapalogs having greater 
      tolerability and micro delivery modes, that hold promise in arresting these age 
      dependent conditions.
FAU - Querfurth, Henry
AU  - Querfurth H
AD  - Department of Neurology, Tufts Medical Center, Boston, Massachusetts, USA. 
      henry.querfurth@tufts.edu.
FAU - Lee, Han-Kyu
AU  - Lee HK
AUID- ORCID: 0000-0002-3787-7995
AD  - Department of Neurology, Tufts Medical Center, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210702
PL  - England
TA  - Mol Neurodegener
JT  - Molecular neurodegeneration
JID - 101266600
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Nerve Degeneration/*metabolism/*pathology
MH  - Neurodegenerative Diseases/*metabolism/*pathology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC8252260
OTO - NOTNLM
OT  - Akt
OT  - Alzheimer's
OT  - Insulin signaling
OT  - Parkinson's
OT  - Rapamycin
OT  - mTOR
COIS- Authors declare that there is no conflict of interest.
EDAT- 2021/07/04 06:00
MHDA- 2022/01/11 06:00
PMCR- 2021/07/02
CRDT- 2021/07/03 05:26
PHST- 2020/05/29 00:00 [received]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/07/03 05:26 [entrez]
PHST- 2021/07/04 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/07/02 00:00 [pmc-release]
AID - 10.1186/s13024-021-00428-5 [pii]
AID - 428 [pii]
AID - 10.1186/s13024-021-00428-5 [doi]
PST - epublish
SO  - Mol Neurodegener. 2021 Jul 2;16(1):44. doi: 10.1186/s13024-021-00428-5.